---
title: "Nucala (mepolizumab), all indications: Safety questions"
description: "Safety questions on Nucala (mepolizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings. Questions: What are the contraindications for Nucala? Does Nucala affect parasitic worm infections? Does Nucala increase the risk of cancer? What happens after a Nucala overdose? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/nucala/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab), all indications: Safety questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)  
Indication pages: [Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)

## Warnings

<a id="nucala-contraindications"></a>

### What are the contraindications for Nucala?

> “NUCALA is contraindicated in patients with a history of hypersensitivity to mepolizumab or 
> excipients in the formulation [see Warnings and Precautions (5.1), Description (11)].”

Source: [NUCALA: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=6)

<a id="nucala-parasitic-infection"></a>

### Does Nucala affect parasitic worm infections?

> “Eosinophils may be involved in the immunological response to some helminth infections. 
> Patients with known parasitic infections were excluded from participation in clinical trials. It is 
> unknown if NUCALA will influence a patient’s response against parasitic infections. Treat 
> patients with pre-existing helminth infections before initiating therapy with NUCALA. If 
> patients become infected while receiving treatment with NUCALA and do not respond to 
> anti-helminth treatment, discontinue treatment with NUCALA until infection resolves.”

Source: [NUCALA: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=6)

## Safety

<a id="nucala-cancer-risk"></a>

### Does Nucala increase the risk of cancer?

> “Long-term animal studies have not been performed to evaluate the carcinogenic potential of 
> mepolizumab. Published literature using animal models suggests that IL-5 and eosinophils are 
> part of an early inflammatory reaction at the site of tumorigenesis and can promote tumor 
> rejection. However, other reports indicate that eosinophil infiltration into tumors can promote 
> tumor growth. Therefore, the malignancy risk in humans from an antibody to IL-5 such as 
> mepolizumab is unknown.”

Source: [NUCALA: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=20)

<a id="nucala-overdose"></a>

### What happens after a Nucala overdose?

> “There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient 
> should be treated supportively with appropriate monitoring as necessary. Consider contacting the 
> Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose 
> management recommendations.”

Source: [NUCALA: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=15)

<a id="nucala-report-side-effects"></a>

### How do I report Nucala side effects?

> “To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or
> FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.”

Source: [NUCALA: SEA Safety Profile, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/safety-profile/#:~:text=To%20report%20SUSPECTED%20ADVERSE%20REACTIONS%2C,FDA%20at%201%2D800%2DFDA%2D1088%20or%20www.fda.gov%2Fmedwatch.)

## Related pages
- [Medical information: Nucala (mepolizumab): All indications](https://www.evicenter.com/medical-information/nucala)
- [Indication](https://www.evicenter.com/medical-information/nucala/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/nucala/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/nucala/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/nucala/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala/access-and-coverage)
